The polycystic ovary syndrome and the metabolic syndrome : a possible chronobiotic-cytoprotective adjuvant therapy

Mostrar todas las versiones(2)

Abstract: Polycystic ovary syndrome is a highly frequent reproductive-endocrine disorder affecting up to 8–10% of women worldwide at reproductive age. Although its etiology is not fully understood, evidence suggests that insulin resistance, with or without compensatory hyperinsulinemia, and hyperand...

Descripción completa

Detalles Bibliográficos
Autores principales: Spinedi, Eduardo J., Cardinali, Daniel Pedro
Formato: Artículo
Lenguaje:Inglés
Publicado: Hindawi 2019
Materias:
SINDROME METABOLICO
MELATONINA
INSULINA
CRONOBIOLOGIA
OVARIOS
ANDRÓGENOS
TEJIDO ADIPOSO
Acceso en línea:https://repositorio.uca.edu.ar/handle/123456789/9089
Aporte de:
Repositorio Institucional de la Universidad Católica Argentina (UCA) de Universidad Católica Argentina
id I33-R139123456789-9089
record_format dspace
institution Universidad Católica Argentina
institution_str I-33
repository_str R-139
collection Repositorio Institucional de la Universidad Católica Argentina (UCA)
language Inglés
topic SINDROME METABOLICO
MELATONINA
INSULINA
CRONOBIOLOGIA
OVARIOS
ANDRÓGENOS
TEJIDO ADIPOSO
spellingShingle SINDROME METABOLICO
MELATONINA
INSULINA
CRONOBIOLOGIA
OVARIOS
ANDRÓGENOS
TEJIDO ADIPOSO
Spinedi, Eduardo J.
Cardinali, Daniel Pedro
The polycystic ovary syndrome and the metabolic syndrome : a possible chronobiotic-cytoprotective adjuvant therapy
topic_facet SINDROME METABOLICO
MELATONINA
INSULINA
CRONOBIOLOGIA
OVARIOS
ANDRÓGENOS
TEJIDO ADIPOSO
description Abstract: Polycystic ovary syndrome is a highly frequent reproductive-endocrine disorder affecting up to 8–10% of women worldwide at reproductive age. Although its etiology is not fully understood, evidence suggests that insulin resistance, with or without compensatory hyperinsulinemia, and hyperandrogenism are very common features of the polycystic ovary syndrome phenotype. Dysfunctional white adipose tissue has been identified as a major contributing factor for insulin resistance in polycystic ovary syndrome. Environmental (e.g., chronodisruption) and genetic/epigenetic factors may also play relevant roles in syndrome development. Overweight and/or obesity are very common in women with polycystic ovary syndrome, thus suggesting that some polycystic ovary syndrome and metabolic syndrome female phenotypes share common characteristics. Sleep disturbances have been reported to double in women with PCOS and obstructive sleep apnea is a common feature in polycystic ovary syndrome patients. Maturation of the luteinizing hormone-releasing hormone secretion pattern in girls in puberty is closely related to changes in the sleep-wake cycle and could have relevance in the pathogenesis of polycystic ovary syndrome. This review article focuses on two main issues in the polycystic ovary syndrome-metabolic syndrome phenotype development: (a) the impact of androgen excess on white adipose tissue function and (b) the possible efficacy of adjuvant melatonin therapy to improve the chronobiologic profile in polycystic ovary syndrome-metabolic syndrome individuals. Genetic variants in melatonin receptor have been linked to increased risk of developing polycystic ovary syndrome, to impairments in insulin secretion, and to increased fasting glucose levels. Melatonin therapy may protect against several metabolic syndrome comorbidities in polycystic ovary syndrome and could be applied from the initial phases of patients’ treatment.
format Artículo
author Spinedi, Eduardo J.
Cardinali, Daniel Pedro
author_facet Spinedi, Eduardo J.
Cardinali, Daniel Pedro
author_sort Spinedi, Eduardo J.
title The polycystic ovary syndrome and the metabolic syndrome : a possible chronobiotic-cytoprotective adjuvant therapy
title_short The polycystic ovary syndrome and the metabolic syndrome : a possible chronobiotic-cytoprotective adjuvant therapy
title_full The polycystic ovary syndrome and the metabolic syndrome : a possible chronobiotic-cytoprotective adjuvant therapy
title_fullStr The polycystic ovary syndrome and the metabolic syndrome : a possible chronobiotic-cytoprotective adjuvant therapy
title_full_unstemmed The polycystic ovary syndrome and the metabolic syndrome : a possible chronobiotic-cytoprotective adjuvant therapy
title_sort polycystic ovary syndrome and the metabolic syndrome : a possible chronobiotic-cytoprotective adjuvant therapy
publisher Hindawi
publishDate 2019
url https://repositorio.uca.edu.ar/handle/123456789/9089
work_keys_str_mv AT spinedieduardoj thepolycysticovarysyndromeandthemetabolicsyndromeapossiblechronobioticcytoprotectiveadjuvanttherapy
AT cardinalidanielpedro thepolycysticovarysyndromeandthemetabolicsyndromeapossiblechronobioticcytoprotectiveadjuvanttherapy
AT spinedieduardoj polycysticovarysyndromeandthemetabolicsyndromeapossiblechronobioticcytoprotectiveadjuvanttherapy
AT cardinalidanielpedro polycysticovarysyndromeandthemetabolicsyndromeapossiblechronobioticcytoprotectiveadjuvanttherapy
bdutipo_str Repositorios
_version_ 1764820529025384449

Ejemplares similares